Stock listing

Frankfurt:96X FluoGuide A/S Aktie

German listing (Frankfurt) of FluoGuide A/S · home listing Stockholm:FLUO

Follow FluoGuide A/S into a list and get an email when it puts out news.

Share price · FWB:96X

€2.45 EUR -0.08 (-3.2%)

Close on Nov 20, 2026

Past year -23.0% · daily closes, Nov 20, 2025 – Nov 6, 2026, adjusted for splits
Day range
€2.45 – €2.48 EURNov 20, 2026
Market cap
€40.06M EURAt the close on Nov 20, 2026 · price × 16.35M shares outstanding
52-week range
€2.45 – €4.19 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
€0 EURMedian day 0 shares · 57 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026
FluoGuide A/S logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
Stockholm:FLUO · Home29.50 SEK-2.10 (-6.6%)7,91329.6029.9029.0031.60Close on Nov 20, 2026
Frankfurt:96X€2.45 EUR-0.08 (-3.2%)—€2.47€2.48€2.45€2.53Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:96X · EUR, adjusted for splits

DayCloseChange%OpenHighLowVolume
€2.56-0.036-1.4%€2.561€2.562€2.5590
€2.596+0.006+0.2%€2.688€2.688€2.5940
€2.59+0.046+1.8%€2.59€2.59€2.590
€2.544-0.103-3.9%€2.554€2.576€2.5280
€2.647+0.011+0.4%€2.642€2.662€2.6260
€2.636+0.059+2.3%€2.646€2.65€2.6230
€2.577-0.069-2.6%€2.576€2.597€2.5450
€2.646+0.104+4.1%€2.62€2.652€2.5950
€2.542+0.025+1.0%€2.572€2.578€2.5350
€2.517-0.09-3.5%€2.556€2.562€2.5080
€2.607-0.008-0.3%€2.606€2.609€2.6050
€2.615+0.057+2.2%€2.615€2.693€2.6130
€2.558-0.022-0.9%€2.525€2.562€2.5250
€2.58+0.011+0.4%€2.532€2.582€2.490
€2.569+0.005+0.2%€2.528€2.57€2.5260
€2.564-0.025-1.0%€2.548€2.568€2.5310
€2.589-0.032-1.2%€2.589€2.603€2.5870
€2.621-0.019-0.7%€2.631€2.675€2.590
€2.64+0.002+0.1%€2.626€2.642€2.6240
€2.638-0.018-0.7%€2.644€2.653€2.6380
€2.656-0.12-4.3%€2.748€2.749€2.6370
€2.776-0.011-0.4%€2.784€2.786€2.7650
€2.787+0.017+0.6%€2.807€2.816€2.6660
€2.77-0.086-3.0%€2.887€2.943€2.7370
€2.856+0.084+3.0%€2.765€2.859€2.6990
€2.772+0.011+0.4%€2.717€2.773€2.7030
€2.761-0.056-2.0%€2.774€2.791€2.7610
€2.817+0.035+1.3%€2.798€2.841€2.7890
€2.782-0.003-0.1%€2.771€2.783€2.7060
€2.785-0.054-1.9%€2.848€2.857€2.7590
€2.839+0.119+4.4%€2.832€2.871€2.7950
€2.72-0.025-0.9%€2.717€2.739€2.7170
€2.745-0.031-1.1%€2.739€2.789€2.7110
€2.776+0.016+0.6%€2.776€2.776€2.7760
€2.76-0.107-3.7%€2.76€2.76€2.760
€2.867+0.093+3.4%€2.835€2.883€2.830
€2.774-0.025-0.9%€2.774€2.774€2.7740
€2.799-0.011-0.4%€2.733€2.816€2.7320
€2.81-0.015-0.5%€2.812€2.812€2.7840
€2.825-0.063-2.2%€2.931€2.951€2.8120
€2.888-0.002-0.1%€2.919€2.935€2.8690
€2.89-0.039-1.3%€2.872€2.918€2.8650
€2.929-0.084-2.8%€3.047€3.07€2.9240
€3.013+0.098+3.4%€2.948€3.051€2.9380
€2.915-0.079-2.6%€2.739€2.925€2.7140
€2.994-0.071-2.3%€2.992€2.999€2.9850
€3.065+0.143+4.9%€3.022€3.078€3.0190
€2.922+0.037+1.3%€2.881€2.958€2.8760
€2.885-0.051-1.7%€2.697€2.896€2.6960
€2.936-0.028-0.9%€2.831€2.954€2.830
€2.964+0.178+6.4%€2.817€2.99€2.8140
€2.786+0.093+3.5%€2.681€2.797€2.6750
€2.693+0.028+1.1%€2.692€2.693€2.680
€2.665-0.062-2.3%€2.608€2.741€2.600
€2.7270.000.0%€2.727€2.727€2.7270
€2.727+0.013+0.5%€2.727€2.727€2.7270
€2.714-0.008-0.3%€2.714€2.714€2.7140
Ticker
Frankfurt:96X
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Frankfurt
Currency
EUR

What changed lately

Latest news

All FluoGuide A/S news

FluoGuide A/S on 6ix

Sector
Health care
Industry
Biotechnology
News releases
17 in the last 12 months · 28 in all · newest Oct 5, 2026 · oldest 2025
Decks
5 decks · latest Jan 21, 2026

Where FluoGuide A/S is listed

ListingExchangeCountryCurrency
Stockholm:FLUO · Home listingStockholmSwedenSEK
Frankfurt:96X · This pageFrankfurtGermanyEUR

Valuation

EV/sales 5,549× against a median of 5.9×: the highest of 6 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
448.8M SEK
P/E
Loss
EV/sales
5,549×
EV/EBITDA
Negative EBITDA
Price/book
10.5×
Gross margin
−772.1%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.9×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
FluoGuide A/S · OMXSTO:FLUOUS$47.27MUS$43.98Mn/a5,549×n/a10.5×n/a0.9×n/a
SYNTHAVERSE Spolka Akcyjna · GPW:SVEUS$48.64MUS$70.93Mn/a5.9×n/a1.7×−43.1%0.8×n/a
Heron Therapeutics, Inc. · NASDAQ:HRTXUS$48.04MUS$156.3Mn/a1.1×n/a9.8×−14.5%26.8×1.93
Helix BioPharma Corp. · TSX:HBPUS$47.94MUS$50.27Mn/an/an/a4.8×n/a0.3×0.36
Oncolytics Biotech Inc. · NASDAQ:ONCYUS$47.66MUS$45.23Mn/an/an/an/an/an/a1.27
THX Pharma · EURONEXT:ALTHXUS$47.21MUS$30.91Mn/an/an/a14.5×n/a0.9×n/a
Rafael Holdings, Inc. · NYSE:RFLUS$47.10MUS$25.00Mn/a28.6×n/a0.7×n/a0.0×0.92
Bio-fd&c Co. Ltd · KRX:251120US$46.46MUS$5.26M9.8×0.4×0.9×0.9×32.8%0.0×n/a
Andros Pharmaceuticals Co., Ltd. · TPEX:6917US$46.02MUS$35.89Mn/a213×n/a3.1×−969.3%0.0×n/a
Werewolf Therapeutics, Inc. · NASDAQ:HOWLUS$46.01MUS$4.14Mn/an/an/a6.8×n/a0.0×1.55
MegaPro Biomedical Co., Ltd. · TPEX:6827US$45.96MUS$43.30Mn/an/an/a7.0×n/a0.0×n/a
Median of the othersUS$47.16MUS$39.59M9.8×5.9×0.9×4.8×−28.8%0.0×1.27

Forecasts

Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.

Price target
54.11 SEK · Analysts' mean
EPS, year to Dec 2026
-3.93 · 1 analyst
Revenue, year to Dec 2026
110K · 2 analysts

Team and board

Officers

OfficerRole
Morten AlbrechtsenChief Executive Officer (CEO)
Ole LarsenChief Financial Officer (CFO)
Donna HaireChief Operating Officer
Andreas KjaerChief Scientific Officer (CSO)

Board

DirectorRole
Peter Mørch EriksenChairman of the board
Andreas KjaerChief Scientific Officer (CSO)
Camilla Harder HartvigMember of the board
Kim Domela KjøllerMember of the board
Mats ThorènVice chairman of the board
Michael EngsigMember of the board

Events

Next results
Nov 26, 2026 (expected)
QuarterResultsShare move
Q2 2026Aug 25, 2026 · After close−7.2%
Q1 2026May 27, 2026 · After close+2.8%
Q4 2025Feb 25, 2026 · Before open0.0%
Q3 2025Nov 27, 2025 · Before open−1.9%
Q2 2025Aug 28, 2025 · Before open+3.8%
Q1 2025May 28, 2025 · Before open−2.8%
Q4 2024Feb 27, 2025 · Before open−4.4%
Q3 2024Nov 27, 2024 · Before open+2.9%
Q2 2024Aug 29, 2024 · Before open−1.2%
Q1 2024May 30, 2024 · Before open−1.3%
All 20 quarters
QuarterResultsShare move
Q4 2023Feb 28, 2024 · Before open−5.2%
Q3 2023Nov 29, 2023 · Before open−3.8%
Q2 2023Aug 30, 2023 · Before open+1.1%
Q1 2023May 31, 2023 · Before open−1.4%
Q4 2022Feb 28, 2023 · Before open+1.7%
Q3 2022Nov 24, 2022 · Before open−0.5%
Q2 2022Aug 25, 2022 · Before open−2.0%
Q1 2022May 31, 2022 · Before open+0.6%
Q4 2021Mar 30, 2022 · Before open+1.3%
Q3 2021Nov 15, 2021 · Before open+0.8%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (January 2026)Investor deck11 slidesJan 21, 2026
Investor Presentation (January 2024)Investor deck51 slidesJanuary 2024
Investor Presentation (February 2023)Investor deck43 slidesFebruary 2023
Investor Presentation (November 2022)Investor deck29 slidesNovember 2022
IPO Roadshow (March 2019)IPO roadshow20 slidesMarch 2019

Open Decks

Financings

RaiseDateIn US dollars
Private placement of shares
Closed: SEK 104M raised · SEK 38 a share · Navia Corporate Finance AB +4
Dealers: Navia Corporate Finance AB (co-lead), Redeye AB (co-lead), Translution Capital (co-lead), Navia Corporate Finance (co-lead), Redeye (co-lead)
Buyers: Several of the Company's major and institutional shareholders (expressed interest in participating with approximately SEK 95 million)
Use of proceeds: Phase II trials of FG001 in HGG in the US and in head and neck cancer, CMC and drug manufacturing for phase III HGG trial, and general corporate purposes
Nov 3, 2025US$10.96M

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in DKK

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue0385.0K423.0K6.51M9.61M0
Cost of revenue571.2K
Gross profit-571.2K385.0K423.0K6.51M9.61M
Research and development18.9M
Selling, general and administrative24.1M20.6M20.6M8.88M
Operating income-41.0M-32.6M-43.7M-32.2M-28.8M-22.2M-10.7M-56.7K
Depreciation and amortization571.2K456.0K265.0K251.0K158.0K119.0K10.6M56.7K
EBITDA-40.4M-32.1M-43.4M-32.0M-28.7M-22.0M-97.0K0
Interest expense4.50M86.0K43.0K175.0K216.0K51.0K965.0K0
Income before tax-46.0M-34.5M-43.9M-32.8M-29.3M-22.2M-11.7M-57.8K
Income tax-5.63M-5.50M-5.50M-5.50M-5.50M-4.73M-2.05M-1.09K
Net income-40.4M-29.0M-38.4M-27.3M-23.8M-17.5M-9.65M-57.8K
Earnings per share, basic-2.87-2.23-3.22-2.33-2.15-1.78-1.49-0.09

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents48.8M18.6M21.7M26.0M46.8M10.6M2.34M59.0K
Short-term investments30.0M200
Receivables5.93M446.0K915.0K3.36M566.0K554.0K2.38M
Current assets86.8M26.5M28.3M34.9M52.8M16.1M4.85M75.0K
Property, plant and equipment53.0K211.0K
Total assets88.3M28.4M29.6M35.6M53.3M16.7M5.24M75.0K
Accounts payable2.68M2.38M4.09M1.60M6.83M2.69M489.0K13.0K
Current liabilities5.73M4.92M16.3M3.65M14.6M12.3M696.0K68.0K
Long-term debt27.6M0
Total debt28.3M624.0K10.8M205.0K57.0K218.0K
Total liabilities33.8M5.31M16.9M3.65M14.6M12.3M696.0K68.0K
Shareholders' equity54.6M23.1M12.7M32.0M38.7M4.41M4.54M7.00K
Shares outstanding14.1M13.0M11.9M11.7M11.0M9.80M6.48M675.3K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-37.8M-29.2M-31.8M-37.6M-15.1M-8.85M-10.6M-1.09K
Capital spending0-850.0K0-64.0K00-378.0K0
Free cash flow-37.8M-30.0M-31.8M-37.7M-15.1M-8.85M-10.9M-1.09K
Cash from investing-30.6M-987.0K-37.0K-117.0K-42.0K-390.0K-390.0K
Cash from financing99.3M27.1M27.5M17.0M51.2M17.2M13.2M65.5K
Change in cash29.1M-3.06M-4.34M-20.7M36.1M8.29M2.29M64.4K

Open Financials

Cap table

Built by 6ix from FluoGuide A/S’ releases · as of Nov 3, 2025

Common shares
16,349,313
Fully diluted
16,349,313

Fully diluted

LineShares
Common shares16,349,313

Share count over time

CountShares
Nov 22, 202616,349,313

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Andreas KjaerChief Scientific Officer (CSO) · Since at least Nov 5, 2026
Camilla Harder HartvigMember of the board · Since at least Mar 10, 2026
Donna HaireChief Operating Officer · Since at least Mar 18, 2026
Kim Domela KjøllerMember of the board · Since at least Mar 10, 2026
Mats ThorènVice chairman of the board · Since at least Mar 10, 2026
Michael EngsigMember of the board · Since at least Mar 10, 2026
Morten AlbrechtsenChief Executive Officer (CEO) · Since at least Oct 5, 2026
Ole LarsenChief Financial Officer (CFO) · Since at least Aug 25, 2026
Peter Mørch EriksenChairman of the board · Since at least Mar 10, 2026

Open People

Log in to ask 6ix AI your own questions about FluoGuide A/S.